Howard Robin - Nektar Therapeutics CEO and President and Director

NKTR Stock  USD 0.84  0.04  5.00%   

CEO

Mr. Howard W. Robin is President, Chief Executive Officer, Director of the Company since 2007.
Age 72
Tenure 18 years
Address 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158
Phone415 482 5300
Webhttps://www.nektar.com
Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a director. From 1991 to 2001, Mr. Robin was Corporationrationrationrate Vice President and General Manager at Berlex Laboratories, Inc., a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer. From 1984 to 1987, Mr. Robin was Director of Business Planning and Development at Berlex. He was a Senior Associate with Arthur Andersen & Co. prior to joining Berlex. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University and serves as a member of its Board of Trustees.

Howard Robin Latest Insider Activity

Tracking and analyzing the buying and selling activities of Howard Robin against Nektar Therapeutics stock is an integral part of due diligence when investing in Nektar Therapeutics. Howard Robin insider activity provides valuable insight into whether Nektar Therapeutics is net buyers or sellers over its current business cycle. Note, Nektar Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nektar Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Nektar Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.2264) % which means that it has lost $0.2264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6163) %, meaning that it created substantial loss on money invested by shareholders. Nektar Therapeutics' management efficiency ratios could be used to measure how well Nektar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/01/2025, Return On Tangible Assets is likely to grow to -0.76. In addition to that, Return On Capital Employed is likely to grow to -0.34. At this time, Nektar Therapeutics' Total Assets are relatively stable compared to the past year. As of 03/01/2025, Non Currrent Assets Other is likely to grow to about 8.3 M, while Other Assets are likely to drop slightly above 2.5 M.
Nektar Therapeutics currently holds 117.78 M in liabilities with Debt to Equity (D/E) ratio of 0.33, which is about average as compared to similar companies. Nektar Therapeutics has a current ratio of 7.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Nektar Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 4 records

CEO Age

Junyuan WangNuvation Bio
51
Jason JDAssembly Biosciences
49
David HungNuvation Bio
63
Jason OkazakiAssembly Biosciences
49
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. Nektar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people. Nektar Therapeutics (NKTR) is traded on NASDAQ Exchange in USA. It is located in 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 and employs 137 people. Nektar Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Nektar Therapeutics Leadership Team

Elected by the shareholders, the Nektar Therapeutics' board of directors comprises two types of representatives: Nektar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nektar. The board's role is to monitor Nektar Therapeutics' management team and ensure that shareholders' interests are well served. Nektar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nektar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jonathan Zalevsky, Senior Vice President - Research , Chief Scientific Officer
Vivian Wu, Director Affairs
Jennifer Ruddock, Vice President - Investor Relations and Corporate Affairs
Mark Wilson, Chief Sec
Sandra Gardiner, Interim Officer
Kevin Brodbeck, VP Operations
Mark JD, Chief VP
Howard Robin, CEO and President and Director
MD LAc, Chief Officer
Brian MD, Interim Officer
John Northcott, Strategic Advisor
Loui Madakamutil, VP Research
Robert Bacci, Senior Operations
Jillian Thomsen, Chief Accounting Officer and Sr. VP of Fin.
Jason Barnard, Chief Officer

Nektar Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nektar Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Nektar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Nektar Stock

  0.71OPT OptheaPairCorr
  0.58LTRN Lantern PharmaPairCorr
  0.52TMO Thermo Fisher ScientificPairCorr
  0.5WAT WatersPairCorr
  0.47VERV Verve TherapeuticsPairCorr
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Nektar Stock Analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.